Abcam Plc (LON:ABC)‘s stock had its “hold” rating restated by equities research analysts at Numis Securities Ltd in a research report issued to clients and investors on Friday. They currently have a GBX 912 ($11.26) price target on the stock. Numis Securities Ltd’s target price suggests a potential upside of 7.67% from the company’s current price.
A number of other research analysts have also recently commented on the company. Peel Hunt started coverage on Abcam Plc in a research report on Wednesday, January 25th. They set a “hold” rating and a GBX 750 ($9.26) price target on the stock. Panmure Gordon reaffirmed a “sell” rating and set a GBX 680 ($8.40) price target on shares of Abcam Plc in a research report on Thursday, January 26th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a GBX 678 ($8.37) price target on shares of Abcam Plc in a research report on Thursday, January 12th. One analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. The stock has an average rating of “Hold” and an average price target of GBX 726 ($8.97).
Abcam Plc (LON:ABC) opened at 839.00 on Friday. The stock’s market capitalization is GBX 1.70 billion. Abcam Plc has a 52 week low of GBX 580.50 and a 52 week high of GBX 948.00. The company has a 50-day moving average of GBX 865.97 and a 200-day moving average of GBX 831.16.
The business also recently disclosed a dividend, which will be paid on Thursday, April 13th. Investors of record on Thursday, March 16th will be paid a dividend of GBX 2.83 ($0.03) per share. The ex-dividend date is Thursday, March 16th. This represents a dividend yield of 0.31%.
About Abcam Plc
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.